XTX Topco’s 4D Molecular Therapeutics FDMT Stock Holding History

XTX Topco’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$893K	Sell	67,122 -16,283	-20%	-$159K	0.01%	1891
2026 Q1	$777K	Buy	83,405 +18,383	+28%	+$160K	0.01%	1636
2025 Q4	$488K	Buy	65,022 +25,039	+63%	+$254K	0.01%	1625
2025 Q3	$347K	Sell	39,983 -38,597	-49%	-$231K	0.02%	1398
2025 Q2	$292K	Buy	+78,580	New	+$276K	0.01%	1455
2025 Q1	–	Sell	-36,939	Closed	-$206K	–	2607
2024 Q4	$206K	Buy	+36,939	New	+$290K	0.02%	1536
2022 Q3	–	Sell	-19,947	Closed	-$139K	–	1173
2022 Q2	$139K	Buy	+19,947	New	+$194K	0.06%	560

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

XTX Topco's FDMT Position: Q2 2026 in Review

XTX Topco reduced its 4D Molecular Therapeutics (FDMT) stake by 20% in Q2 2026, selling an estimated $159K and leaving 67,122 shares worth $893K. The position accounts for 0.01% of the portfolio, ranked #1891.

XTX Topco first reported a position in FDMT in Q2 2022 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

XTX Topco held 67,122 shares of 4D Molecular Therapeutics worth $893K as of Q2 2026.
XTX Topco sold 16,283 4D Molecular Therapeutics shares in Q2 2026, an estimated $159K.
4D Molecular Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1891 holding.
XTX Topco first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 7 quarters since.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.